anti-BR3 mAbs (Biogen/Genentech)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-BR3 mAbs (Biogen/Genentech)
Drug Alias NameBAFF mAbs (Biogen/Genentech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen IncGenentech Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A